GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PharmaResearch Co 214450.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

236,000

+0.64%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩536.29bn

FY2016FY2025

Net income

₩165.12bn

FY2016FY2025

Free cash flow

₩147.38bn

FY2016FY2025

Shareholders' equity

₩689.33bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩536.29bn₩350.12bn₩261.01bn₩194.76bn₩154.08bn₩108.75bn₩83.87bn₩64.28bn₩54.47bn₩45.95bn
Gross profit₩411.22bn₩251.24bn₩190.26bn₩141.51bn₩108.33bn₩72.90bn₩50.11bn₩38.22bn₩36.06bn₩30.84bn
Research and development₩35.86bn₩21.18bn₩15.03bn₩8.70bn₩6.74bn₩5.54bn₩5.61bn₩4.04bn₩4.50bn₩3.38bn
Operating income₩214.40bn₩125.60bn₩89.14bn₩60.80bn₩51.65bn₩32.17bn₩19.06bn₩7.84bn₩13.96bn₩14.11bn
Net income₩165.12bn₩92.04bn₩76.55bn₩40.58bn₩46.69bn₩32.77bn₩16.67bn₩14.41bn₩12.96bn₩13.91bn
Diluted earnings per share15,892.838,898.067,510.534,067.474,680.143,395.231,766.601,523.171,387.131,479.44

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩1.04trn₩855.70bn₩535.28bn₩478.06bn₩427.65bn₩319.83bn₩269.93bn₩258.19bn₩189.03bn₩179.33bn
Cash and short-term investments—₩437.35bn₩160.30bn₩184.34bn₩156.80bn₩79.27bn₩69.03bn₩75.40bn₩87.61bn₩109.98bn
Total liabilities₩320.01bn₩286.26bn₩73.09bn₩134.55bn₩122.20bn₩74.41bn₩60.85bn₩60.56bn₩10.18bn₩7.69bn
Debt₩434.3m₩209.47bn₩34.31bn₩66.77bn₩65.61bn₩32.41bn₩20.94bn₩20.36bn——
Shareholders' equity₩689.33bn₩539.40bn₩433.10bn₩343.50bn₩305.44bn₩245.42bn₩209.07bn₩197.62bn₩178.85bn₩171.64bn
Shares outstanding10m10m10m10m10m10m9m9m9m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩183.16bn₩139.88bn₩64.95bn₩59.40bn₩65.30bn₩32.39bn₩19.27bn₩5.20bn₩8.56bn₩8.16bn
Capital spending−₩35.78bn−₩38.73bn−₩13.20bn−₩17.76bn−₩20.64bn−₩34.78bn−₩9.59bn−₩28.60bn−₩7.63bn−₩1.96bn
Free cash flow₩147.38bn₩101.15bn₩51.75bn₩41.65bn₩44.65bn−₩2.39bn₩9.69bn−₩23.39bn₩924.3m₩6.20bn
Dividends paid−₩11.73bn−₩10.09bn−₩7.53bn−₩6.32bn−₩5.03bn−₩2.96bn−₩2.97bn−₩2.80bn−₩2.82bn−₩1.89bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩178.70bn₩146.10bn₩143.35bn₩135.43bn₩140.61bn₩116.91bn₩103.08bn₩89.21bn
Gross profit₩137.55bn₩112.93bn₩109.43bn₩109.14bn₩107.20bn₩85.45bn₩75.65bn₩64.56bn
Operating income₩66.53bn₩57.57bn₩51.91bn₩61.87bn₩55.88bn₩44.54bn₩33.24bn₩34.92bn
Net income₩56.57bn₩47.57bn₩32.57bn₩48.97bn₩47.40bn₩36.17bn₩18.69bn₩24.72bn
Diluted earnings per share5,445.084,579.013,134.944,713.534,562.663,481.701,799.172,390.00
Cash from operations₩33.05bn₩31.21bn₩61.53bn₩47.11bn₩39.06bn₩35.46bn₩39.46bn₩33.78bn
Capital spending−₩13.09bn−₩8.87bn−₩7.79bn−₩6.91bn−₩7.18bn−₩13.90bn−₩13.30bn−₩5.70bn
Free cash flow₩19.97bn₩22.33bn₩53.74bn₩40.20bn₩31.89bn₩21.56bn₩26.16bn₩28.08bn
Total assets₩1.11trn₩1.09trn₩1.04trn₩988.30bn₩923.24bn₩889.45bn₩855.70bn₩640.82bn
Cash and short-term investments—————₩458.57bn₩437.35bn₩216.41bn
Debt₩423.7m₩432.8m₩434.3m₩442.7m₩455.0m₩199.03bn₩197.24bn₩9.11bn
Shareholders' equity₩753.67bn₩696.90bn₩689.33bn₩660.99bn₩611.56bn₩564.31bn₩539.40bn₩510.03bn

Financial ratios

Data as of 26 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross margin76.7%71.8%72.9%72.7%70.3%67.0%———
Operating margin40.0%35.9%34.2%31.2%33.5%29.6%———
Net margin30.8%26.3%29.3%20.8%30.3%30.1%———
Return on equity24.0%17.1%17.7%11.8%15.3%13.4%———
Return on assets15.8%10.8%14.3%8.5%10.9%10.2%———
Free cash flow yield——————0.7%0.8%0.4%
Revenue growth53.2%34.1%34.0%26.4%41.7%29.7%———
Earnings growth79.4%20.2%88.7%-13.1%42.5%96.6%———
Current ratio6.88x6.70x3.89x4.56x4.31x3.55x———
Debt to equity0.00x0.00x0.00x0.18x0.19x0.10x———
Equity ratio66.0%63.0%80.9%71.9%71.4%76.7%———
Interest coverage20.63x27.10x29.84x15.88x39.32x18.01x———
R&D as a share of sales6.7%6.0%5.8%4.5%4.4%5.1%———
Buybacks as a share of market value——————0.3%-1.3%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue40.2%37.6%30.5%
Operating income52.2%46.1%29.6%
Net income59.7%38.2%29.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin74.7%74.1%73.2%71.7%
Operating margin38.4%36.5%35.7%34.1%
Net margin29.0%27.9%28.3%27.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings25.429.514.617.217.516.920.622.142.527.3
Price to sales7.87.84.33.65.35.14.15.010.18.3

Dividends and splits

Per share, in the currency the company pays

Paid for 11 years. Last went ex-dividend on 29 Dec 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year3,700.002,050.00660.00600.00500.00300.00300.00300.00

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.